化学性质：                                                                                                             

产品描述：                                                                                                            

Cefotaxime, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria[1][2][3][4][2].

Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6[4].

The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens[4]. Animal Model: Female, specific pathogen free, 8-week-old BALB/c mice[4].

[1]. Hee-Chang Jang, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One. 2014 Jun 30;9(6):e101118. [2]. Woodfield JC, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9. [3]. Scholz H, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7. [4]. Gums JG, et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother. 2008 Jan;42(1):71-9. [5]. E L Francke, et al. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. Am J Med. 1981 Sep;71(3):435-42.

特别提醒：